Principal Financial Group
XERS icon

Principal Financial Group’s Xeris Biopharma Holdings XERS Stock Holding History

Principal Financial Group’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.8M Buy
227,418
+18,911
+9% +$121K ﹤0.01% 1862
2026
Q1 		$1.21M Buy
208,507
+57,948
+38% +$384K ﹤0.01% 1901
2025
Q4 		$1.18M Buy
150,559
+45,066
+43% +$355K ﹤0.01% 1926
2025
Q3 		$859K Sell
105,493
-48,444
-31% -$322K ﹤0.01% 1955
2025
Q2 		$719K Buy
153,937
+40,191
+35% +$184K ﹤0.01% 1938
2025
Q1 		$624K Buy
113,746
+529
+0.5% +$2.13K ﹤0.01% 1903
2024
Q4 		$384K Buy
113,217
+10,748
+10% +$34.6K ﹤0.01% 2000
2024
Q3 		$292K Buy
102,469
+23,843
+30% +$61.2K ﹤0.01% 2029
2024
Q2 		$177K Sell
78,626
-10,992
-12% -$22.2K ﹤0.01% 2157
2024
Q1 		$198K Buy
89,618
+44,893
+100% +$116K ﹤0.01% 2182
2023
Q4 		$105K Buy
44,725
+1,601
+4% +$2.96K ﹤0.01% 2269
2023
Q3 		$80.2K Sell
43,124
-2,166
-5% -$4.96K ﹤0.01% 2311
2023
Q2 		$119K Buy
45,290
+30,325
+203% +$77.2K ﹤0.01% 2266
2023
Q1 		$24.4K Sell
14,965
-1,029
-6% -$1.29K ﹤0.01% 2413
2022
Q4 		$21.3K Sell
15,994
-70,054
-81% -$98.9K ﹤0.01% 2398
2022
Q3 		$134K Sell
86,048
-90,079
-51% -$149K ﹤0.01% 2275
2022
Q2 		$271K Buy
+176,127
New +$372K ﹤0.01% 2211
2021
Q4 		– Sell
-11,801
Closed -$29K – 2656
2021
Q3 		$29K Sell
11,801
-1,915
-14% -$5.56K ﹤0.01% 2559
2021
Q2 		$56K Buy
+13,716
New +$52.3K ﹤0.01% 2566
2021
Q1 		– Sell
-11,344
Closed -$56K – 2507
2020
Q4 		$56K Buy
+11,344
New +$56.8K ﹤0.01% 2389

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Principal Financial Group's XERS Position: Q2 2026 in Review

Principal Financial Group increased its Xeris Biopharma Holdings (XERS) stake by 9.1% in Q2 2026, buying an estimated $121K and bringing the position to 227,418 shares worth $1.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1862.

Principal Financial Group first reported a position in XERS in Q4 2020 and has held it in 20 quarters since. 240 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Principal Financial Group held 227,418 shares of Xeris Biopharma Holdings worth $1.8M as of Q2 2026.
  • Principal Financial Group bought 18,911 Xeris Biopharma Holdings shares in Q2 2026, an estimated $121K.
  • Xeris Biopharma Holdings made up ﹤0.01% of Principal Financial Group's portfolio in Q2 2026, its #1862 holding.
  • Principal Financial Group first reported a position in Xeris Biopharma Holdings in Q4 2020 and has held it in 20 quarters since.
  • 240 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.